Gilead Sciences develops and commercializes medicines for HIV, viral hepatitis, COVID-19 and cancer. Company updates regularly cover product sales and operating results, HIV franchises such as Biktarvy, Yeztugo and lenacapavir, and clinical or regulatory activity for investigational HIV regimens that combine established antiretroviral agents with newer mechanisms.
Recurring developments also include oncology pipeline expansion through Kite cell-therapy programs, the completed acquisition of Arcellx and its investigational BCMA-directed CAR T-cell therapy anitocabtagene autoleucel for multiple myeloma, collaboration activity using real-world evidence in oncology R&D, shareholder matters, and capital-structure disclosures tied to material agreements and acquisitions.
Gilead Sciences (Nasdaq: GILD) announced a collaboration with TelevisaUnivision and the Latin GRAMMY Awards to promote HIV testing and prevention awareness.
The Ahorita Mismo! campaign, part of Gilead’s Care for the Culture initiative, focuses on Latino communities. Planned activities include a red-carpet presence, celebrity interviews, a Despierta America segment and a social-media docuseries featuring Santi Casas. Community events in Los Angeles, Miami, Dallas and Houston will connect participants with HIV prevention education and resources.
BridgeBio Pharma (BBIO) has a November 27, 2026 FDA target action date for BBP-418, opening a five-company year-end review calendar. The application covers limb-girdle muscular dystrophy type 2I/R9 and has priority review.
Vertex Pharmaceuticals (VRTX) has a November 30 target for povetacicept in IgA nephropathy, also under priority review. Gilead Sciences (GILD) has a December 23 target for anito-cel in relapsed or refractory multiple myeloma. Viatris (VTRS) has a December 27 goal for fast-acting meloxicam in moderate-to-severe acute pain. Praxis Precision Medicines (PRAX) has a December 27 target for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies.
These are FDA action targets, not approval decisions. Recent updates also included raised 2026 outlooks at Vertex, Gilead and Viatris, alongside additional regulatory milestones in 2027.
Gilead Sciences (Nasdaq: GILD) reported higher one-year persistence with twice-yearly lenacapavir than daily oral F/TDF in the PURPOSE 5 HIV-prevention trial. Persistence means consistent, continuous on-time use. At Week 52, persistence was 85.6% versus 46.3%, respectively (p<0.0001). The ongoing, randomized, open-label Phase 2 study enrolled 267 participants in the United Kingdom and France who were not taking pre-exposure prophylaxis (PrEP), medication used to prevent HIV.
Zero HIV acquisitions occurred with lenacapavir during 52 weeks; one occurred with F/TDF, with drug levels consistent with fewer than two doses weekly. Serious adverse events occurred in 3.9% and 3.4%, respectively; investigators considered none treatment-related. No lenacapavir participants discontinued because of adverse events. Mild or moderate injection-site reactions were the most common treatment-related events. The findings will be presented at HIV Glasgow 2026.
Gilead Sciences (GILD) reported Phase 3 IDEAL results showing improved liver biomarker normalization with Livdelzi in primary biliary cholangitis (PBC).
At Week 52, 75.4% (49/65) receiving Livdelzi met the primary composite endpoint versus 16.1% (5/31) receiving placebo. This required alkaline phosphatase (ALP), a disease-activity marker, at or below the upper limit of normal and a reduction of at least 15% from baseline. The trial enrolled 96 adults with ALP above normal but below 1.67 times that limit despite ursodeoxycholic acid treatment or with intolerance to it.
Response appeared after one month: 52.3% versus 6.5% with placebo. Serious adverse events occurred in 3.1% versus 12.9%, respectively; none were deemed trial-drug related. Gilead is engaging global regulators on the results. Livdelzi has accelerated U.S. approval; improved survival or prevention of liver decompensation has not been demonstrated.
Merck (NYSE: MRK) reported worldwide sales of $18.1 billion, up 5%, and narrowed its sales outlook while raising the midpoint. Its expected sales range is $66.8 billion–$67.3 billion. KEYTRUDA/KEYTRUDA QLEX sales were $8.6 billion; WINREVAIR sales rose 93% to $694 million.
Other drugmakers also reported growth: Amgen's third-quarter revenue rose 8% to $10.4 billion, Vertex's rose 12% to $3.44 billion, and Incyte's rose 14% to $1.56 billion. Gilead's product sales excluding Veklury increased 16% year over year to $8.2 billion. Gilead, Vertex and Incyte raised their full-year sales or revenue outlooks. Pricing pressures included a 14% decline in Amgen's Enbrel net selling price; Gilead expects a new Medicare price to affect Biktarvy revenue starting January 1, 2028.
The Nasdaq Biotechnology Index rose 2.1% as of 2:31 p.m. ET on November 4, alongside a broader market rally.
Gilead Sciences (GILD) and Kite will present 23 presentations at the American Society of Hematology annual meeting on December 12–15, 2026. Seven are oral presentations.
The program includes 18-month minimum follow-up from the Phase 2 iMMagine-1 study of investigational anito-cel in multiple myeloma after three or more prior treatment lines. The study supports a U.S. approval application under FDA review, with a December 23, 2026 target decision date. Other presentations include five-year ZUMA-12 follow-up evaluating Yescarta as first-line treatment for high-risk large B-cell lymphoma, and initial clinical experience from two ongoing Phase 1b studies of gamgertamig in relapsed or refractory autoimmune blood disorders. The announcement provides presentation topics rather than numerical efficacy or safety results.
Gilead Sciences (Nasdaq: GILD) will present HIV prevention, treatment and cure research at HIV Glasgow, taking place November 8–11, 2026. The program includes results from more than 50 studies, including Phase 3 ARTISTRY and ISLEND analyses, real-world Biktarvy evidence and Phase 1b cure research.
A PURPOSE 5 abstract reports higher persistence with twice-yearly lenacapavir than daily F/TDF for HIV prevention in the UK and France. Presentations will cover one-year persistence and safety. BIC/LEN received U.S. FDA approval as Bixlenvo in August 2026; ISL/LEN remains an investigational once-weekly oral treatment. GS-3242, being evaluated with lenacapavir as a potential twice-yearly injectable treatment in two Phase 2 studies, received FDA fast-track designation in October 2026.
Gilead Sciences (Nasdaq: GILD) executives will speak at five investor conferences during November and December 2026. Appearances include Wolfe Research on November 10, UBS and Jefferies on November 17, Citi on December 1 and Evercore on December 2. Live webcasts will be available on the company’s investor relations website, with replays available for at least 30 days after each presentation.
Gilead Sciences (Nasdaq: GILD) reported third-quarter 2026 product sales of $8.3 billion, up 13% from the same period in 2025. Sales excluding Veklury rose 16% to $8.2 billion, while HIV sales increased 18% to $6.2 billion. Diluted earnings per share fell to $1.94 from $2.43, despite higher product gross margin.
Gilead raised its 2026 product-sales outlook to $31.0 billion–$31.3 billion from $30.1 billion–$30.4 billion, but widened its expected diluted loss per share to $4.05–$4.40 from $3.40–$3.75. Guidance includes approximately $9.88 per share from acquisition-related research charges, net of the Lakefront collaboration and related taxes. Cash, cash equivalents and marketable debt securities fell to $6.4 billion from $10.6 billion at year-end 2025. Updates included FDA approval of HIV treatment Bixlenvo and European authorization of Trodelvy with Keytruda for specified breast cancer patients.
Gilead Sciences (GILD) agreed to acquire PepStar Therapeutics’ investigational oral IL-23R inhibitor program for $1.275 billion in upfront cash.
The acquisition includes worldwide rights to lead asset HCXT-2001, currently in Phase 1 clinical trials. The oral peptide targets the IL-23 receptor, a target involved in immune-mediated inflammatory diseases. Gilead sees potential for the asset as a daily oral treatment for inflammatory bowel disease, alone or combined with other programs, including emvistegrast.
The upfront payment is due at closing and subject to customary adjustments. Gilead expects closing in the fourth quarter of 2026, subject to customary conditions, and an approximately $0.79 to $0.83 reduction in GAAP and non-GAAP earnings per share that quarter. HCXT-2001’s safety and efficacy have not been established, and it has no regulatory approval.